109906
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
肿瘤相关自身抗体抗 p53 与肺腺癌患者的不良预后相关
Authors Jing K, Ouyang L, Cai J, Zheng P, Li G, Wang R
Received 2 July 2025
Accepted for publication 21 October 2025
Published 7 November 2025 Volume 2025:17 Pages 2665—2674
DOI https://doi.org/10.2147/CMAR.S540712
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Professor Harikrishna Nakshatri
Keying Jing, Libo Ouyang, Jun Cai, Peiming Zheng, Gang Li, Rong Wang
Department of Clinical Laboratory, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, Zhengzhou, People’s Republic of China
Correspondence: Rong Wang, Email wangrong36602010@163.com
Purpose: There is a known association between tumor-associated autoantibodies (TAAbs) and lung cancer. TAAbs are currently used in clinical settings for the early detection of lung cancer. However, the relationship between TAAbs profiles and clinical outcomes in lung cancer patients remains incompletely understood. This study aims to investigate the association between TAAbs and survival rates in individuals diagnosed with lung adenocarcinoma.
Patients and Methods: This study enrolled 161 patients diagnosed with lung adenocarcinoma at Henan Province People’s Hospital between January 2020 and December 2022. Levels of TAAbs were measured using a commercial enzyme-linked immunosorbent assay (ELISA) kit. Follow-up data were collected through December 2024. The association between TAAbs levels and disease progression was evaluated using Kaplan–Meier survival analysis and Cox proportional hazards models.
Results: In the univariate analysis, the presence of p53 autoantibodies (anti-p53) and CAGE autoantibodies (anti-CAGE) was associated with an increased risk of reduced progression-free survival (PFS). In the multivariate analysis, anti-p53 remained significantly associated with shorter PFS, while anti-CAGE was not correlated with poor prognosis. The significant association between anti-p53 and worse PFS persisted after adjusting for gender, age, smoking status, pathological stage, and treatment. Kaplan–Meier survival analysis further confirmed that patients positive for anti-p53 had significantly shorter PFS (P = 0.0025).
Conclusion: Tumor-associated autoantibody anti-p53 correlates poor prognosis in lung adenocarcinoma patients, offering novel insights into tumor prognosis.
Keywords: lung adenocarcinoma, autoantibodies associated with lung cancer, prognosis, progression-free survival
Department of Clinical Laboratory, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, Zhengzhou, People’s Republic of China
Correspondence: Rong Wang, Email wangrong36602010@163.com
Purpose: There is a known association between tumor-associated autoantibodies (TAAbs) and lung cancer. TAAbs are currently used in clinical settings for the early detection of lung cancer. However, the relationship between TAAbs profiles and clinical outcomes in lung cancer patients remains incompletely understood. This study aims to investigate the association between TAAbs and survival rates in individuals diagnosed with lung adenocarcinoma.
Patients and Methods: This study enrolled 161 patients diagnosed with lung adenocarcinoma at Henan Province People’s Hospital between January 2020 and December 2022. Levels of TAAbs were measured using a commercial enzyme-linked immunosorbent assay (ELISA) kit. Follow-up data were collected through December 2024. The association between TAAbs levels and disease progression was evaluated using Kaplan–Meier survival analysis and Cox proportional hazards models.
Results: In the univariate analysis, the presence of p53 autoantibodies (anti-p53) and CAGE autoantibodies (anti-CAGE) was associated with an increased risk of reduced progression-free survival (PFS). In the multivariate analysis, anti-p53 remained significantly associated with shorter PFS, while anti-CAGE was not correlated with poor prognosis. The significant association between anti-p53 and worse PFS persisted after adjusting for gender, age, smoking status, pathological stage, and treatment. Kaplan–Meier survival analysis further confirmed that patients positive for anti-p53 had significantly shorter PFS (P = 0.0025).
Conclusion: Tumor-associated autoantibody anti-p53 correlates poor prognosis in lung adenocarcinoma patients, offering novel insights into tumor prognosis.
Keywords: lung adenocarcinoma, autoantibodies associated with lung cancer, prognosis, progression-free survival